<DOC>
	<DOCNO>NCT00624754</DOCNO>
	<brief_summary>The usual treatment obstructive airway disease ( OAD ) allogeneic hematopoietic stem cell transplantation ( AHSCT ) , relate graft versus host disease ( GVHD ) , consist intensification systemic immunosuppressive therapy .</brief_summary>
	<brief_title>Prospective Evaluation Efficacy Budesonide/Formoterol Bronchiolitis Obliterans AHSCT</brief_title>
	<detailed_description>Although evaluate prospectively , usual treatment obstructive airway disease ( OAD ) allogeneic hematopoietic stem cell transplantation ( AHSCT ) , relate graft versus host disease ( GVHD ) , consist intensification systemic immunosuppressive therapy . However , treatment limit efficacy associate significant number serious adverse effect , particularly infectious . Alternative treatment therefore necessary.We retrospectively report clinical functional improvement patient OAD follow AHSCT treat inhaled budesonide/formoterol combination.These encouraging result need confirmed present randomise , prospective double-blind trial . This study therefore design evaluate efficacy budesonide/formoterol versus placebo patient moderate severe OAD , require initiation intensification systemic immunosuppressive therapy extra thoracic GVHD . Inclusion criterion modify accord amendment 02/11/2009</detailed_description>
	<mesh_term>Bronchiolitis</mesh_term>
	<mesh_term>Bronchiolitis Obliterans</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Age ≥16 year . Previous normal PFTs available . Absence extrathoracic GVH disease justify initiation intensification systemic immunosuppressive therapy . Respiratory sign present less 6 month . AHSCT recipient develop moderate severe bronchiolitis obliterans , define reduction FEV1/VC 5th percentile predict normal &lt; 80 % predict , FEV1 &lt; 80 % predict ≥ 40 % predict , reversible inhalation shortacting beta2 agonist . AHSCT recipients FEV1 &lt; 80 % predict ≥ 40 % predict , reversible inhalation shortacting beta2 agonist TLC ≥ 80 % predict . Respiratory symptom related obstructive lung disease present least 6 month . Negative respiratory microbiology workup . Informed consent sign patient parent minor . Extrathoracic graft versus host reaction justify initiation intensification systemic immunosuppressive therapy . Use inhale bronchodilator and/or corticosteroid therapy time inclusion . Known intolerance inhaled bronchodilator and/or corticosteroid and/or lactose . Personal donor history asthma . Active smoking FEV1 &lt; 40 % predict normal ≥ 80 % predict normal PO2 &lt; 50 mmHg . Documented respiratory tract infection . Pregnancy . Absence effective contraception trial . Not cover French national health insurance .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Obstructive airway disease</keyword>
	<keyword>bronchiolitis obliterans</keyword>
	<keyword>allogeneic hematopoietic stem cell transplantation</keyword>
	<keyword>bone marrow transplantation</keyword>
	<keyword>inhale treatment</keyword>
	<keyword>Budesonide Formoterol</keyword>
</DOC>